EXCELLENT CLINICAL AND PHARMACOKINETIC REAL-WORLD EXPERIENCE AFTER SWITCHING TO DAMOCTOCOG ALFA PEGOL

被引：0
|
作者：
Hidalgo, O. Benitez [1 ]
Gimenez, J. C. Juarez [2 ]
机构：
[1] Vall Hebron Univ Vall, Hemophilia Unit, Hematol Dept, Barcelona, Spain
[2] Vall Hebron Univ Vall, Pharm Deparment, Barcelona, Spain
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO048
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [1] Excellent Clinical and Pharmacokinetic Real-World Experience after Switching to Rurioctocog ALFA Pegol
    Hidalgo, Olga Benitez
    Jaime, Francisco Jose Lopez
    Garcia, Maria Fernanda Martinez
    Gimenez, Juan Carlos Juarez
    Martinez, Eva Alvarez
    Suito, Milagros
    Bosch, Francesc
    Mesa, Mercedes Gironella
    BLOOD, 2020, 136
  • [2] EXCELLENT REAL-WORLD EXPERIENCE AFTER PHARMACOKINETIC GUIDED SWITCH FROM STANDARD HALF - LIFE TO RURIOCTOCOG ALFA PEGOL
    Benitez Hidalgo, O.
    Lopez Jaime, F.
    Martinez Garcia, M. F.
    Suito Alcantara, M.
    Alvarez Martinez, E.
    Juarez Gimenez, J. C.
    HAEMOPHILIA, 2021, 27 : 75 - 76
  • [3] GERMAN CLINICAL EXPERIENCE OF SWITCHING FROM OCTOCOG ALFA TO DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH HAEMOPHILIA A
    Marquardt, N.
    Goldmann, G.
    Herbst, K.
    Nadal, J.
    Oldenburg, J.
    HAEMOPHILIA, 2023, 29 : 97 - 97
  • [4] Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset
    Chandler, Martin
    Charlet, Jessica
    Moulton, Thomas
    Recht, Michael
    BLOOD, 2022, 140 : 2751 - 2752
  • [5] PHARMACOKINETIC REAL-WORLD EXPERIENCE AFTER SWITCHING TO ALBUTREPENONACOG ALFA USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL
    Benitez Hidalgo, O.
    Juarez Gimenez, J. C.
    Alvarez Roman, M. T.
    Romero Garrido, J. A.
    Gomez del Castillo, M. D. C.
    Gonzalez Pinero, S.
    Montoro, J. B.
    HAEMOPHILIA, 2023, 29 : 46 - 46
  • [6] REAL-WORLD EFFECTIVENESS OF DAMOCTOCOG ALFA PEGOL IN MILD AND MODERATE HEMOPHILIA A PATIENTS AGED 12 YEARS AND OLDER IN THE ATHNDATASET
    Chandler, Martin
    Charafi, Lena
    Moulton, Thomas
    Recht, Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E18 - E19
  • [7] Danish clinical experience of switching from standard half-life FVIII to damoctocog alfa pegol in patients with haemophilia A
    Poulsen, L. H.
    Adamsen, I.
    HAEMOPHILIA, 2024, 30 : 102 - 102
  • [8] CANADIAN CLINICAL EXPERIENCE ON SWITCHING FROM OCTOCOG ALFA TO EXTENDED-HALF-LIFE FVIII DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE HAEMOPHILIA A
    Iorio, A.
    Matino, D.
    Decker, K.
    Iserman, E.
    Keepanasseril, A.
    Germini, F.
    Chan, A. K. C.
    Walsh, L.
    HAEMOPHILIA, 2022, 28 : 43 - 43
  • [9] Positive clinical impact after switching to turoctocog alfa pegol: Iberian experience
    Benitez Hidalgo, O.
    Lopez Jaime, F. J.
    Perez Gonzalez, N. F.
    Canaro Hirnyk, M.
    Aguilar Franco, C.
    Delgado Garcia, A.
    Fernandez Sanchez de Mora, M. C.
    del Castillo Solano, M. C. Gomez
    Gonzalez Porras, J. R.
    Marcellini Antonio, S.
    Marco Rico, A.
    Nieto, M. D. M.
    Rodriguez Lopez, M.
    Nobre Fernandes, S.
    HAEMOPHILIA, 2024, 30 : 111 - 112
  • [10] Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
    Sanabria, Martin
    Alvarez Roman, Maria Teresa
    Castaman, Giancarlo
    Janbain, Maissaa
    Matsushita, Tadashi
    Meijer, Karina
    Oldenburg, Johannes
    Friedl, Sabine
    Reding, M. T.
    BMJ OPEN, 2021, 11 (09):
12345